PHILADELPHIA — (Jan. 13, 2021) — Scientists at The Wistar Institute discovered that Early Growth Response 1 (EGR1), a protein that turns on and off specific genes during blood cell development, inh…
PHILADELPHIA — (Jan. 12, 2021) — Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade…
PHILADELPHIA — (Jan. 7, 2021) — Scientists at The Wistar Institute characterized an inhibitor that targets acetate metabolism in cancer cells. Cancer cells use acetate metabolism to support tumor g…
PHILADELPHIA — (Dec. 15, 2020) — A team of scientists from The Wistar Institute, INOVIO, AstraZeneca, the Perelman School of Medicine at the University of Pennsylvania, and Indiana University has r…
PHILADELPHIA — (Oct. 29, 2020) — Scientists at The Wistar Institute have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus (POWV), targeting portions of the vir…
PHILADELPHIA — (Oct. 13, 2020) — Researchers at The Wistar Institute and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic r…
PHILADELPHIA — (Oct. 13, 2020) — The Wistar Institute is pleased to welcome Scott Cooper, Ph.D., Richard G. Phillips Jr., Esq., and Steven V. Abramson, to its Board of Trustees. The new trustees br…
PHILADELPHIA — (Sept. 30, 2020) — Researchers at The Wistar Institute unraveled a mechanism employed by chronic lymphocytic leukemia (CLL) cells for their survival. According to the study, publishe…
PHILADELPHIA — (Sept. 14, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease research, and vaccine creation, announces the appointme…
PHILADELPHIA — (Sept. 10, 2020) — Combining their expertise in protein engineering and synthetic DNA technology, scientists at The Wistar Institute successfully delivered nanoparticle antitumor vac…
